shingles
4 stories
-
healthEli Lilly Invests $3.83 Billion in Vaccine Biotechs
Eli Lilly acquires three vaccine biotechs for up to $3.83bn to target shingles, antimicrobial resistance, and Epstein-Barr virus.
-
healthRoutine Vaccines Could Reduce Dementia Risk: The Trained Immunity Hypothesis
A new hypothesis suggests routine vaccines may lower dementia risk by training the innate immune system, a process called trained immunity.
-
healthShingles: A Painful Reality Beyond the Rash
Discover the serious health risks and lingering pain associated with shingles, a viral condition that affects adults over 50. Learn about symptoms and the importance of early treatment.
-
healthChurch Outreach Boosts Shingles Vaccine Confidence in Vulnerable Adults
Faith-based education program significantly improves recombinant zoster vaccine knowledge and intent among at-risk communities in California.